ICU Medical Q4 revenue up slightly but net loss widens; provides FY2024 guidance

ICU MEDICAL INC/DE

2023-FY EPS reported -$1.23 revenue$2,259,126,000

Revenue $587.9M in Q4 2023, up 1.7% YoY from $578.0M.
GAAP net loss $17.1M ($0.71/share) widened from $15.5M loss ($0.65/share) in Q4 2022.
Adjusted EBITDA $86.3M vs $96.4M YoY; adjusted EPS $1.57 vs $1.60.
Gross margin slipped to 29% from 30%; gross profit $171.6M vs $174.9M.
Company issued FY2024 guidance (not detailed in excerpt).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ICU MEDICAL INC/DE reported fourth quarter of 2023 results: revenue $587.9 million, net income $(17.1) million, EPS $(0.71) per diluted share.

Period: fourth quarter of 2023
Revenue: $587.9 million
Net income: $(17.1) million
EPS: $(0.71) per diluted share
Result: reported results

Exact text from the filing

and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the same

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

ICU MEDICAL INC/DE filing history →

Source: SEC EDGAR

accession 0000883984-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.